Merck bags a PhIII CMV victory in the wake of a flop at rival Chimerix
Four years after bagging the late-stage drug letermovir in a $571 million deal, Merck says the drug has come through in a lengthy Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
